The HIV Vaccine's Path Through Clinical Trials: A Biotech CEO's Perspective

Drs. Benjamin Levy and Alex Spira discuss the emerging role of TROP2 as a therapeutic target in non-small cell lung cancer (NSCLC) on ReachMD. They delve into the mechanisms and clinical implications of TROP2-targeted antibody-drug conjugates (ADCs), highlighting ongoing clinical trials evaluating their safety and efficacy. The conversation covers the potential of these therapies to change treatment paradigms, especially in the context of TROP2 overexpression associated with poor prognosis in lung cancers. They also address the nuances of managing side effects and the importance of understanding TROP2's role in cancer regulation, underscoring the significance of keeping up-to-date with the latest clinical trial data in this rapidly evolving field.

Dive into the forefront of precision oncology with Drs. Pasi Janne and Jyoti Patel, where they unravel the potential of HER3-directed antibody-drug conjugates (ADCs) in revolutionizing treatment for NSCLC. Discover the transformative potential of HER3-directed ADCs in overcoming resistance to EGFR-targeted TKI therapies. This program offers a unique blend of trial results and practical strategies through the lens of a clinical case. Join us to lead the change in cancer care.

Dr. Helena Yu of Memorial Sloan Kettering Cancer Center presents an insightful overview of HER2 targeted therapy in non-small cell lung cancer (NSCLC), emphasizing the critical role of broad molecular profiling in ensuring effective treatment, particularly for the 2-4% of NSCLC patients with HER2 mutations. Dr. Yu highlights the effectiveness of newer antibody–drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd) for NSCLC with HER2 mutations, while also detailing identification and management of potential side effects. Through a patient engagement vignette, she underscores the importance of aligning treatment choices with patient and clinician goals, highlighting shared decision-making in managing HER2-mutant NSCLC.

We now have FDA approved targeted therapies to treat NSCLC with EGFR exon 20 insertion mutations. Drs. Wakelee and Bazhenova discuss the most current data on both approved therapies and drugs in development.

We now have an FDA-approved targeted therapy to treat HER2-mutated NSCLC. Drs. Aggarwal and Sands discuss the most current clinical data, including management of adverse events.

Drs. Paul Paik, Keith Kerr, and Ross Camidge take us through testing considerations for MET exon 14 skipping mutations and optimal treatment approaches once a mutation is detected. They also discuss the emerging data and how to apply what we’re learning to everyday clinical practice.

This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.

This program provides education to help clinicians confidently diagnose and make informed clinical decisions with their patients, ultimately enhancing clinical outcomes in the evolving treatment landscape of ADCs across the continuum of Triple Negative Breast Cancer (TNBC).

In addition, a patient education solution is available to complete the curriculum by providing clinician-developed videos. Clinicians electronically prescribe these convenient videos to patients. Expert providers answer top questions faced by patients with breast cancer in a trustworthy, evidence-based format.

Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.

This program provides education to help clinicians confidently diagnose and make informed clinical decisions with their patients, ultimately enhancing clinical outcomes in the evolving treatment landscape of ADCs across the continuum of Triple Negative Breast Cancer (TNBC).

In addition, a patient education solution is available to complete the curriculum by providing clinician-developed videos. Clinicians electronically prescribe these convenient videos to patients. Expert providers answer top questions faced by patients with breast cancer in a trustworthy, evidence-based format.

Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.

This program provides education to help clinicians confidently diagnose and make informed clinical decisions with their patients, ultimately enhancing clinical outcomes in the evolving treatment landscape of ADCs across the continuum of Triple Negative Breast Cancer (TNBC).

In addition, a patient education solution is available to complete the curriculum by providing clinician-developed videos. Clinicians electronically prescribe these convenient videos to patients. Expert providers answer top questions faced by patients with breast cancer in a trustworthy, evidence-based format.

Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.